Nxera Pharma Co Employees 2024

Nxera Pharma Co Aktienanalyse

What does Nxera Pharma Co do?

The Sosei Group Corp. is a Japanese company that operates in the fields of pharmaceutical research and development. It was founded in 1990 as Photonamic GmbH & Co KG in Munich, Germany, before being renamed Sosei Co. Ltd. in 2003. The company is headquartered in Tokyo, Japan, and operates research and development facilities in Japan, the United Kingdom, and Denmark. Sosei is involved in several significant drug development projects and has produced some successful products in the past. Business model: The main focus of the Sosei Group Corp. is the research and development of pharmaceuticals. Its primary business model is to be involved in the entire value chain of drug development, from the discovery and characterization of new drug candidates to clinical development and regulatory approval. In order to attract partners in the pharmaceutical and biotech industry, the company offers its core competencies in drug research and development, including optimizing drug candidates and conducting clinical trials. Partnerships can be structured in the form of strategic alliances, licensing fees, milestone payments, and profit sharing. Divisions: The Sosei Group Corp. divides its activities into three main divisions: 1. Sosei Heptares: The company is a leading player in G-protein-coupled receptor (GPCR) research and development. GPCRs are a class of membrane proteins involved in regulating signal transduction processes and are of significant importance in drug development. Sosei Heptares provides its expertise and technology platform to third parties for developing new drugs targeting GPCR. 2. Sosei R&D: Sosei R&D focuses on the discovery and development of new drug candidates in various therapeutic areas, including inflammation, oncology, pain, respiratory, and mental disorders. The company utilizes its proprietary technology platform, which includes computer-aided design and synthesis optimization, to identify and develop new drugs. 3. Sosei CMC: The Sosei CMC department is responsible for developing customized processes for manufacturing pharmaceuticals. It encompasses all aspects of drug manufacturing, from formulation to manufacturing techniques. The department also works closely with other departments of the company to ensure that the drug products meet the highest quality and safety standards. Products: Sosei has developed and brought to market some successful drugs in the past. These include medications such as: 1. NVA237 (glycopyrronium bromide): An inhalation medicine for the treatment of chronic obstructive pulmonary disease (COPD). 2. QVA149 (indacaterol/glycopyrronium bromide): Another inhalation medicine approved for the treatment of COPD. 3. Sovodakso (GSK-491876): A drug candidate developed in partnership with GlaxoSmithKline (GSK) currently under investigation in phase III clinical trials for the treatment of schizophrenia. 4. Aclidinium bromide: An inhalation medicine for the treatment of COPD, developed in partnership with Almirall. In summary, the Sosei Group Corp. is a leading player in pharmaceutical research and development. The company focuses on developing novel drugs for the treatment of a variety of diseases and works closely with partners in the pharmaceutical and biotech industry. With its extensive knowledge and technological expertise, Sosei is one of the few companies capable of overcoming the challenges in drug development. Nxera Pharma Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Nxera Pharma Co's Employee Base

Nxera Pharma Co's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Nxera Pharma Co's operational capacity and future potential.

Year-to-Year Comparison

Assessing Nxera Pharma Co's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Nxera Pharma Co's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Nxera Pharma Co’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Nxera Pharma Co stock

How many employees does Nxera Pharma Co have this year?

Nxera Pharma Co has 190 undefined employees this year.

How many employees did Nxera Pharma Co have compared to the previous year?

Compared to the previous year, Nxera Pharma Co had 0% more employees.

What impact did the number of employees have on the company Nxera Pharma Co?

The number of employees has a direct impact on the efficiency and productivity of Nxera Pharma Co. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Nxera Pharma Co?

The number of employees can also have an impact on investors of Nxera Pharma Co, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Nxera Pharma Co affect the company?

An increase in equity of Nxera Pharma Co can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Nxera Pharma Co's equity affect the company?

A reduction in equity of Nxera Pharma Co can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Nxera Pharma Co?

Some factors that can influence the equity of Nxera Pharma Co include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Nxera Pharma Co so important for investors?

The equity of Nxera Pharma Co is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Nxera Pharma Co influence the company?

The number of employees at Nxera Pharma Co can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Nxera Pharma Co evolved in recent years?

In recent years, the number of employees at Nxera Pharma Co has changed by 0.

How many employees does Nxera Pharma Co currently have?

Nxera Pharma Co currently has 190 undefined employees.

Why is the number of employees important for investors of Nxera Pharma Co?

The number of employees is important for investors of Nxera Pharma Co as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Nxera Pharma Co take to change the number of employees?

To change the number of employees, Nxera Pharma Co can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Nxera Pharma Co pay?

Over the past 12 months, Nxera Pharma Co paid a dividend of 2.5 JPY . This corresponds to a dividend yield of about 0.2 %. For the coming 12 months, Nxera Pharma Co is expected to pay a dividend of 0 JPY.

What is the dividend yield of Nxera Pharma Co?

The current dividend yield of Nxera Pharma Co is 0.2 %.

When does Nxera Pharma Co pay dividends?

Nxera Pharma Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nxera Pharma Co?

Nxera Pharma Co paid dividends every year for the past 0 years.

What is the dividend of Nxera Pharma Co?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nxera Pharma Co located?

Nxera Pharma Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nxera Pharma Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nxera Pharma Co from 6/24/2015 amounting to 10 JPY, you needed to have the stock in your portfolio before the ex-date on 3/27/2015.

When did Nxera Pharma Co pay the last dividend?

The last dividend was paid out on 6/24/2015.

What was the dividend of Nxera Pharma Co in the year 2023?

In the year 2023, Nxera Pharma Co distributed 0 JPY as dividends.

In which currency does Nxera Pharma Co pay out the dividend?

The dividends of Nxera Pharma Co are distributed in JPY.